Outlook on Some Heterocyclic Scaffolds and Their Anti-Diabetic Activity
Keywords:
Diabetes mellitus, Hyperglycemia, AMPK, NIDDM, Thiazolidinediones, FlavonoidsAbstract
In the next decade, a significantly greater percentage of new drugs based on nitrogen and sulfur will be developed. Novel N-heterocyclic moieties have a wide range of intriguing applications in medicinal chemistry, as well as significant physiological properties. In this review, we've compiled the most recent findings on novel five- and six-membered heterocycles with nitrogen and sulfur atoms, as well as their distinct antidiabetic activities that have been reported over the past few years. This review focuses on trends in drug design related to five- and six-membered heterocycles, having anti-diabetic activity.
Keywords: Diabetes mellitus, Hyperglycemia, AMPK, NIDDM, Thiazolidinediones, Flavonoids
References
1. Ogurtsova, K.; da Rocha Fernandes, J.D.; Huang, Y.; Linnenkamp, U.; Guariguata, L.; Cho, N.H.; Cavan, D.; Shaw, J.E.; Makaroff, L.E. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res. Clin. Pract. 2017, 128, 40–50.
2. Colao, A., Pivonello, C. and Riccio, E., 2022. Diabetes Insipidus. In Endocrine Pathology (pp. 174-176). Cham: Springer International Publishing.
3. Abu-Nejem, R. and Hannon, T.S., 2024. Insulin Dynamics and Pathophysiology in Youth-Onset Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism, 109(10), pp.2411-2421.
4. Balaji, R., Duraisamy, R. and Kumar, M.P., 2019. Complications of diabetes mellitus: A review. Drug Invention Today, 12(1).
5. Clifford J Bailey; Biguanides and NIDDM. Diabetes Care 1 June 1992; 15 (6): 755–772. https://doi.org/10.2337/diacare.15.6.755
6. Rena, G., Hardie, D.G. & Pearson, E.R. The mechanisms of action of metformin. Diabetologia 60, 1577–1585 (2017). https://doi.org/10.1007/s00125-017-4342-z
7. Scott A. Gabel, Michael R. Duff, Lars C. Pedersen, Eugene F. DeRose, Juno M. Krahn, Elizabeth E. Howell, and Robert E. London Biochemistry 2017 56 (36), 4786-4798 DOI: 10.1021/acs.biochem.7b00619
8. Bruce R. Zimmerman, SULFONYLUREAS, Endocrinology and Metabolism Clinics of North America, Volume 26, Issue 3, 1997, Pages 511-522, ISSN 0889-8529, https://doi.org/10.1016/S0889-8529(05)70264-4.
9. Tomlinson, B., Patil, N. G., Fok, M., Chan, P., & Lam, C. W. K. (2021). The role of sulfonylureas in the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy, 23(3), 387–403. https://doi.org/10.1080/14656566.2021.1999413
10. Sarah D. Corathers, Shawn Peavie, MarziehSalehi, Complications of Diabetes Therapy,
11. Endocrinology and Metabolism Clinics of North America, Volume 42, Issue 4, 2013, Pages 947-970,ISSN 0889-8529, ISBN 9780323260947, https://doi.org/10.1016/j.ecl.2013.06.005.
12. Máire E Doyle 1, Josephine M Egan Pharmacological agents that directly modulate insulin secretion Pharmacol Rev, 2003 Mar;55(1):105-31. doi: 10.1124/pr.55.1.7.
13. "FDA Approves New Treatment for Diabetes" (Press release). U.S. Food and Drug Administration. October 17, 2006. Retrieved 2006-10-17.
14. Bernd Richter Elizabeth Bandeira‐EchtlerKarlaBergerhoffChristianLerch, Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus Version published: 23 April 2008 Version history https://doi.org/10.1002/14651858.CD006739.pub2
15. Makrilakis K. The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect. International Journal of Environmental Research and Public Health. 2019; 16(15):2720. https://doi.org/10.3390/ijerph16152720
16. Mulvihill, E.E. and Drucker, D.J., 2014. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocrine reviews, 35(6), pp.992-1019.
17. https://images.app.goo.gl/Amb8ZL8vAUmEjMVb6
18. Simes, B.C. and MacGregor, G.G., 2019. Sodium-glucose cotransporter-2 (SGLT2) inhibitors: a clinician’s guide. Diabetes, metabolic syndrome and obesity: targets and therapy, pp.2125-2136.
19. Popovic-Djordjevic, J.B., Jevtic, I.I. and Stanojkovic, T.P., 2018. Antidiabetics: Structural diversity of molecules with a common aim. Current Medicinal Chemistry, 25(18), pp.2140-2165.
20. El Masri, D., Ghosh, S. and Jaber, L.A., 2018. Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 137, pp.83-92.
21. Liu, B., Wang, Y., Zhang, Y. and Yan, B., 2019. Mechanisms of protective effects of SGLT2 inhibitors in cardiovascular disease and renal dysfunction. Current Topics in Medicinal Chemistry, 19(20), pp.1818-1849.
22. Jain, V.S., Vora, D.K. and Ramaa, C.S., 2013. Thiazolidine-2, 4-diones: Progress towards multifarious applications. Bioorganic & medicinal chemistry, 21(7), pp.1599-1620.
23. dasNeves, A.M., Campos, J.C., Gouvêa, D.P., Berwaldt, G.A., Goulart, T.B., Avila, C.T., Machado, P., Zimmer, G.C. and Cunico, W., 2019. Synthesis of Novel Thiazolidin‐4‐ones and Thiazinan‐4‐ones Analogous to Rosiglitazone. Journal of Heterocyclic Chemistry, 56(1), pp.251-259.
24. Nirwan, S., Chahal, V. and Kakkar, R., 2019. Thiazolidinones: Synthesis, reactivity, and their biological applications. Journal of Heterocyclic Chemistry, 56(4), pp.1239-1253.
25. Soccio, R.E., Chen, E.R. and Lazar, M.A., 2014. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell metabolism, 20(4), pp.573-591.
26. Naz, R., Saqib, F., Awadallah, S., Wahid, M., Latif, M.F., Iqbal, I. and Mubarak, M.S., 2023. Food polyphenols and type II diabetes mellitus: pharmacology and mechanisms. Molecules, 28(10), p.3996.
27. Sarkar, D., Christopher, A. and Shetty, K., 2022. Phenolic bioactives from plant-based foods for glycemic control. Frontiers in endocrinology, 12, p.727503.
28. Baur, J.A., Pearson, K.J., Price, N.L., Jamieson, H.A., Lerin, C., Kalra, A., Prabhu, V.V., Allard, J.S., Lopez-Lluch, G., Lewis, K. and Pistell, P.J., 2006. Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 444(7117), pp.337-342.
29. Crozier, A., Yokota, T., Jaganath, I.B., Marks, S., Saltmarsh, M. and Clifford, M.N., 2006. Secondary metabolites in fruits, vegetables, beverages and other plant based dietary components. Plant secondary metabolites: Occurrence, structure and role in the human diet, pp.208-302.
30. Brodowska, K.M., 2017. Natural flavonoids: classification, potential role, and application of flavonoid analogues. European Journal of Biological Research, 7(2), pp.108-123.
31. Sok Yen, F., Shu Qin, C., Tan Shi Xuan, S., Jia Ying, P., Yi Le, H., Darmarajan, T., Gunasekaran, B. and Salvamani, S., 2021. Hypoglycemic effects of plant flavonoids: a review. Evidence‐Based Complementary and Alternative Medicine, 2021(1), p.2057333.
32. Bhambhani, S., Kondhare, K.R. and Giri, A.P., 2021. Diversity in chemical structures and biological properties of plant alkaloids. Molecules, 26(11), p.3374.
33. Shrivastava, S., Sharma, A., Saxena, N., Bhamra, R. and Kumar, S., 2023. Addressing the preventive and therapeutic perspective of berberine against diabetes. Heliyon, 9(11)
34. Rai, S., Acharya-Siwakoti, E., Kafle, A., Devkota, H.P. and Bhattarai, A., 2021. Plant-derived saponins: a review of their surfactant properties and applications. Sci, 3(4), p.44.
35. Allen, E., Xie, Z., Gustafson, A.M. and Carrington, J.C., 2005. microRNA-directed phasing during trans-acting siRNA biogenesis in plants. Cell, 121(2), pp.207-221.
36. Feng, Y., Ren, Y., Zhang, X., Yang, S., Jiao, Q., Li, Q. and Jiang, W., 2024. Metabolites of traditional Chinese medicine targeting PI3K/AKT signaling pathway for hypoglycemic effect in type 2 diabetes. Frontiers in Pharmacology, 15, p.1373711.
